PITTSBURGH , April 29, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat rare skin diseases announces presentations of clinical data for KB103 to treat dystrophic epidermolysis bullosa, and preclinical data on KB105 for

First EMA PRIME eligibility for Krystal Biotech Eligibility based on positive primary analysis of clinical and non clinical data to date PRIME Designation allows for frequent and early interactions with the EMA aimed at supporting accelerated evaluation and approval PITTSBURGH , March 29, 2019

Topline-data from Phase 1/2 clinical trial of KB103 (bercolagene telserpavec) for treatment dystrophic epidermolysis bullosa (DEB) to be announced in 1H 2019 Ancoris, a cGMP facility for clinical and commercial production of KB103, is operational following successful completion of a trial run.

New facility expected to meet all clinical and commercial development needs of lead program KB103 A second, larger cGMP facility expected to be completed in 2020 to meet all anticipated future pipeline production requirements PITTSBURGH , March 06, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc.

PITTSBURGH , March 04, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , ( Krystal ) (NASDAQ: KRYS), a gene therapy company developing “off-the-shelf” treatments for rare dermatological diseases, announced that Julian S. Gangolli has been elected to Krystal’s Board of Directors and will serve as a

PITTSBURGH , March 01, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S.

PITTSBURGH , Feb. 22, 2019 (GLOBE NEWSWIRE) --   Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S.

PITTSBURGH , Jan. 15, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare dermatological diseases, today announces that construction of Ancoris, a new state-of-the-art Good

Top line results from GEM-Phase 2 study expected in H1 2019 PITTSBURGH , Dec. 19, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare dermatological diseases, today announces that

PITTSBURGH , Nov. 20, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S.